Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Hanwha Ocean (042660) – Correction of Decision on Acquisition of Shares or Equity Securities of Other Corporations by Subsidiary / 2024-12-30

Posted on December 30, 2024August 8, 2026 By K-STOCK Editor No Comments on [Disclosure] Hanwha Ocean (042660) – Correction of Decision on Acquisition of Shares or Equity Securities of Other Corporations by Subsidiary / 2024-12-30

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Hanwha Ocean has disclosed a correction updating the target acquisition date to undecided (to be disclosed via amended filing once finalized) regarding the equity investment by its US subsidiary (Hanwha Ocean USA Holdings Corp.) into Hanwha Ocean USA International LLC.

📊 [Key Disclosure Details & Financial Highlights]

  • Correction Classification: Corrected Filing (Report)
  • Correction Filing Date: December 30, 2024
  • Original Disclosure Document & Date: Decision on Acquisition of Shares or Equity Securities of Other Corporations by Subsidiary (June 14, 2024)
  • Reason for Correction: Change in target acquisition date
  • Major Corrected Items:
    • Target Acquisition Date: December 31, 2024, before correction → Undecided after correction (to be disclosed via amended filing once final completion date is fixed)
  • Subsidiary (Disclosing Entity) Details:
    • Subsidiary Name: Hanwha Ocean USA Holdings Corp. (CEO: Yeon-Seong Jang / Main Business: Maritime Service / Major Subsidiary: Yes)
    • Parent Consolidated Total Assets: KRW 13,944,800,000,000 (approx. KRW 13.94T, as of FY2023 consolidated financials)
  • Target Company Information:
    • Company Name: Hanwha Ocean USA International LLC (Nationality: USA / CEO: Yeon-Seong Jang / Main Business: Maritime Service)
    • Relationship: Affiliated Company
  • Acquisition Details:
    • Acquisition Amount: KRW 363,300,000,000 (approx. KRW 363.3B / USD 265,000,000, applying exchange rate of KRW 1,371.00/USD)
    • Total Assets: KRW 13,944,800,000,000 (approx. KRW 13.94T, as of FY2023 consolidated financials)
    • Acquisition Amount to Total Assets Ratio: 2.6%
    • Method of Acquisition: Participation in Rights Issue to Shareholders (Cash acquisition)
    • Purpose of Acquisition: Participation in capital increase to secure operating funds and investment capital
    • Board Resolution Date: June 13, 2024 (Board approval date of Hanwha Ocean USA Holdings Corp.)
  • Other Important Notes:
    • Equity investment decision for the capital increase of Hanwha Ocean USA International LLC, a 100%-owned subsidiary
    • Converted KRW amount applies the exchange rate as of June 14, 2024 (1 USD = KRW 1,371.00) and may fluctuate based on exchange rates at actual execution
    • Target entity was newly incorporated in 2023
    • Subsidiary total assets reflect the balance sheet as of March 31, 2024; an investment of USD 17.3M was completed on April 4, 2024
    • Related Disclosures: June 14, 2024 (Decision on Acquisition of Shares or Equity Securities of Other Corporations by Subsidiary & Decision on Capital Increase by Subsidiary)

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Target Acquisition Date Revision and Subsequent Filings

This correction disclosure notifies the market that the target acquisition date for the subsidiary’s equity investment was changed to undecided, with an amended filing scheduled once the final completion date is confirmed. Verifying whether a subsequent corrected disclosure is filed with the finalized acquisition date in accordance with project progress is essential for tracking the actual execution status of the subsidiary’s cross-border equity transaction. Related details can be verified in upcoming official regular filings, including Quarterly, Half-Yearly, and Annual Reports.

📢 Disclaimer & Fact Source

Source: This content was structured and newly written based on officially submitted data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Disclaimer: This material is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Shipbuilding

Post navigation

Previous Post: [Disclosure] Hanwha Ocean (042660) – Correction of Decision on Acquisition of Shares or Equity Securities of Other Corporations by Subsidiary / 2024-12-30
Next Post: [Disclosure] Hanwha Ocean (042660) – Correction of Decision on Acquisition of Shares or Equity Securities of Other Corporations / 2024-12-30

Related Posts

[Disclosure] SK Hynix (000660) – Results of Annual General Meeting of Shareholders / 2025-03-27 Semiconductors
[Disclosure] Hanwha Aerospace (012450) Evades Unfaithful Disclosure Designation Regarding Paid-in Capital Increase Revision, Receives Cautionary Notice Disclosures
[Disclosure] Samsung Biologics (207940) – Setting of Record Date or Period for Suspension of Entry of Change in Shareholders / 2025-12-16 Disclosures
[Disclosure] Hanwha Aerospace (012450) – Clarification on Rumors or News Reports (Unconfirmed Re-disclosure Regarding KRW 18T Poland Export Reports) Disclosures
[Disclosure] Hanwha Ocean (042660) – Provisional Financial Results (Fair Disclosure) / 2025-07-29 Disclosures
[Disclosure] Samsung Biologics (207940) – (Correction) Major Management Matters Related to Investment Decisions / 2024-03-27 Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme